Skip to main
TELA

TELA Stock Forecast & Price Target

TELA Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

TELA Bio is showing promising growth with Q4/25 revenue up 18% year-over-year, driven by new customer additions, the US launch of larger-sized OviTex PRS products, and international sales growth. Their OviTex unit sales and PRS unit sales also showed healthy increases of 20% and 12%, respectively. Despite falling slightly below gross margin estimates, the company's EPS of ($0.17) was above consensus estimates.

Bears say

TELA Bio is facing significant challenges with their sales force restructuring and strategic challenges, as evidenced by their lowered 2026 outlook and continued contraction in their stock. While their portfolio may offer potential, execution remains a key concern and it may take time for their new strategy to gain traction and drive revenue growth, leading to a cautious outlook on the stock. Furthermore, the company's dependence on regulatory approvals, potential for future losses and dilution, and uncertainty surrounding reimbursement for their products add additional layers of risk for investors to consider.

TELA has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TELA Bio, Inc. (TELA) Forecast

Analysts have given TELA a Buy based on their latest research and market trends.

According to 4 analysts, TELA has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TELA Bio, Inc. (TELA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.